businessbriefs
SubjectsAll subjects on briefs.cloud →
Saved
Companies · Strategy

Sun Pharma

1983

Sun Pharma proves that global scale in generics isn’t built on patents or pipelines — it’s built on factories, filings, and foot soldiers in FDA, EMA and CDSCO exam rooms.

Worth your time?4/5Yes.Study the whole thing.What works, what does not, who it is for ↓
11:29in productionCh. 1 · Scale, certified/ 11:29 · ceiling 15 min
4 chapters · 11:29Ceiling 15:00

The brief is written and checked. The video joins this page when it is cut.4 chapters · 1 min read · 11:29 planned

Read the brief

Sun Pharma is a vertically distributed generic drug manufacturer whose scale is real, verifiable, and geographically dispersed — but whose economics, margins, and strategic vulnerabilities remain undocumented in the source material.

CompaniesStrategyGlobalisationSupply chainsPhotographyGlobalisation across the network →
Chapters & takeaways4
  1. 1:10
    Scale, certified

    Sun Pharma is India’s largest pharma company and the world’s fourth largest specialty generic player — a claim verified by its own documentation.

  2. 3:19
    Global reach, concentrated revenue

    70% of revenue is international, but over 60% of turnover still comes from just two countries: the US and India.

  3. 5:24
    Factories before flags

    43 manufacturing sites across six continents signal operational complexity — not just ambition.

  4. 7:24
    Therapeutic sprawl as infrastructure

    15 therapeutic areas covered means breadth, not depth — a portfolio strategy for regulatory and reimbursement arbitrage.

1 more chapterFewer chapters
Worth your time?

Yes. Study the whole thing.

4/ 5
What works
  • geographic revenue split
  • manufacturing footprint
  • therapeutic coverage
  • market position claims
What does not
  • financial performance
  • R&D investment
  • regulatory outcomes
  • pricing power
Study it if
  • investors assessing operational scale
  • policy analysts studying generic market structure
  • competitors benchmarking manufacturing footprint
Skip it if
  • those seeking valuation signals
  • analysts needing margin data
  • journalists investigating corporate conduct
Who should study it, and who should skipHide who it is for
The written brief1 min read

What the company or idea is

Sun Pharma is an Indian multinational pharmaceutical company, founded in 1983 and headquartered in Mumbai. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.

How it actually makes money

Sun Pharma makes money by manufacturing and selling generic pharmaceutical formulations and active pharmaceutical ingredients (APIs) in over 100 countries. Around 70% of its revenue comes from international markets, with the US and India alone accounting for over 60% of turnover.

What works

Its global manufacturing presence — 43 locations across India, the US, Asia, Africa, Australia and Europe — enables local supply and regulatory alignment. Its product portfolio spans 15 therapeutic areas, including psychiatry, oncology, dermatology and ophthalmology, allowing cross-market leverage.

What does not

The material does not establish how Sun Pharma prices its products, what its margins are, how much it spends on R&D or regulatory compliance, or how it manages supply-chain risk across 43 manufacturing sites. It says nothing about profitability, debt, or shareholder returns.

What to take from it

Scale in generics is defined by manufacturing footprint and therapeutic coverage — not innovation or branding. Sun Pharma’s model rests on volume, regulatory approvals across jurisdictions, and distribution in high-volume markets like the US and India.

Is it worth your time

Yes — if you are assessing how scale, geographic diversification, and therapeutic breadth operate in the global generics business without relying on hype or unverified financial claims.

Same desk · Companies4 of 325
9:31
PSA Group1976PSA Group was a French automotive manufacturer formed in 1976 when Peugeot took control of Citroën. It expanded through acquisition — Chrysler Europe (1978), Opel and Vauxhall (2017) — and alliances, notably with General Motors (2012). It rebranded as PSA Group in 2016 and attempted to re-enter North America, but merged with Fiat Chrysler Automobiles in 2021 to form Stellantis. Its strategy prioritised scale over self-sustaining regional operations.
10:49
Daiichi Sankyo2005Daiichi Sankyo is a post-merger pharmaceutical entity whose scale derives from consolidation — not innovation velocity. Its revenue is large, its global reach documented, but its growth levers are acquisitions and inherited assets. Its 2015 $39 million kickback settlement signals real regulatory exposure — not just theoretical compliance risk.
10:34
Novo Nordisk1923Novo Nordisk is a Danish multinational pharmaceutical company, founded in 1989 through the merger of two 1920s-origin insulin firms. It manufactures and markets pharmaceutical products and services, primarily for diabetes and obesity. Its first major device innovation was the Novopen insulin pen, launched in 1985. The 1989 merger made it the world’s largest insulin producer. Its headquarters are in Bagsværd.
9:40
Aurobindo Pharma1986Aurobindo Pharma is a vertically integrated manufacturer of generic drugs and APIs—not a branded pharma company, not a biotech innovator, and not a vertically integrated global marketer. Its business model is built on regulatory filing speed, cost discipline, and third-party commercialisation. It scales by making what others have already proved safe and effective—and doing it cheaper, faster, and across more geographies than most rivals.
Up next in Business

Suncor Energy

1917 · 11:11

Suncor isn’t a pioneer—it’s a consolidation play built on one province’s tar sands and two governments’ exits.

Next brief →Back to Companies
11:11